Hana Biosciences issued Talotrexin patent

By Lisa Kerner

Erie, Pa., Feb. 14 - Hana Biosciences Inc. said it was issued U.S. Patent No. 6,989,386 from the U.S. Patent and Trademark Office directed to its Talotrexin compositions and methods of using Talotrexin compositions.

"We are thrilled to have a very strong patent position for our lead product, Talotrexin, and expect additional patents to issue, positioning us with a very firm intellectual property estate," president and chief executive officer Mark Ahn said in a company news release.

Talotrexin (PT-523) is a novel nonpolyglutamatable antifolate drug with demonstrated antitumor activity. It targets DHFR to prevent DNA synthesis and inhibit tumor growth, the company said.

Compared to currently available antifolates in preclinical studies, Talotrexin enters into cells up to 10 times more efficiently and binds more tightly to its anti-tumor target DHFR, which enhances efficacy.

Hana said a phase 1 trial in solid tumors, phase 1/2 in non-small cell lung cancer and a phase 1/2 in acute lymphocytic leukemia are ongoing. Phase 2 trials in cervical, endometrial and ovarian cancers are forthcoming.

Hana is a South San Francisco biopharmaceutical company that is focused on advancing cancer care.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.